Kinpeygo

Budesonide, the active ingredient in Kinpeygo, is a glucocorticoid presented as an oral formulation for oral use. It is employed to manage inflammatory bowel diseases, specifically Crohn's disease and ulcerative colitis, in adult patients.

GNH USA supplies Kinpeygo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet the needs of healthcare providers across multiple regions. Kinpeygo is manufactured under EU Good Manufacturing Practice guidelines and distributed through GNH USA's global logistics network.

Kinpeygo (budesonide) is used in the management of inflammatory bowel disease, targeting intestinal inflammation.

- Crohn's disease: induces remission and reduces intestinal inflammation. - Ulcerative colitis: controls disease activity and promotes mucosal healing. - Inflammatory bowel disease (IBD): provides overall disease control for patients with moderate to severe disease. - Maintenance therapy: helps maintain remission after induction therapy.

Budesonide may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Nausea - Headache - Abdominal pain - Upper respiratory tract infection

Serious or Rare Side Effects: - Adrenal suppression - Severe infections - Hypersensitivity reactions

When prescribing Budesonide, clinicians should consider several safety measures to minimise risk.

- Monitor adrenal function: assess for signs of insufficiency during prolonged therapy. - Assess for infections: avoid use in patients with active systemic infections. - Use lowest effective dose: limit exposure to reduce systemic effects. - Caution in osteoporosis: evaluate bone health and consider prophylaxis if needed. - Store at room temperature: keep in the original pack, protect from moisture.

Budesonide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure. - Live vaccines: risk of infection due to immunosuppression. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness. - Diuretics: may increase risk of hypokalemia.